Cronos Group Inc. (CRON) is a Canadian cannabis company that grows, processes, and sells cannabis and cannabis-derived products, best known for its Spinach consumer brand and a growing international medical business. Its shares trade on the Nasdaq and on the Toronto Stock Exchange. After a sharp run toward the top of its 52-week range, the question many investors are asking is whether the stock can push to a $3.75 price target.
Four current, individually attributed analyst price targets were reviewed for the U.S.-listed shares. Bernstein carries a Hold with a $2.47 target, Canaccord Genuity has a Buy at $3.05, Roth MKM holds a Buy at $3.58, and TD Cowen maintains a Buy at $3.94. The arithmetic mean of these four is about $3.26, which is slightly below the current share price, so it does not meet the minimum distance required for a meaningful upside scenario.
Applying the minimum-distance rule, the two targets above the current price — $3.58 (Roth MKM) and $3.94 (TD Cowen) — average to roughly $3.76, rounded to the $3.75 central target used in this analysis. Notably, TD Securities raised its Canadian-dollar target to C$7.00 (approximately US$5.00) in late September 2026, indicating some analysts see materially more upside than the headline average implies. The dispersion between a cautious $2.47 Hold and bullish targets above $3.90 reflects genuine disagreement about the durability of the company's recent growth.
The stock recently closed near $3.35, within its 52-week range of roughly $2.28 to $3.61. Reaching $3.75 would require about a 12% advance — a modest but meaningful move that would take the shares to a fresh high above the $3.61 range top. The company's market capitalization is roughly $1.2 billion, and its balance sheet holds close to $800 million in cash with minimal debt, meaning a large share of the market value is backed by cash rather than operating earnings. With trailing EPS (earnings per share) around $0.19 and a P/E (price-to-earnings) ratio near 17, valuation is modest but hinges on sustaining recent profitability.
Cronos reported a record quarter in August 2026, posting EPS of $0.09 versus a $0.01 consensus estimate on revenue of about $53 million, which beat forecasts. Management has credited international momentum in markets such as Israel, Germany, and Australia, alongside Canadian market-share gains in vape and edibles led by the Spinach brand. The company has been profitable on an EPS basis for multiple consecutive quarters, a turnaround from prior losses, and its net cash position gives it flexibility to fund growth, pursue partnerships, or consider consolidation options in a rapidly evolving industry.
The most immediate obstacle is earnings trajectory. Consensus estimates for the upcoming quarter imply EPS falling to roughly $0.03 from $0.09 in the prior quarter, and one data provider notes the next-quarter revenue estimate has been revised downward in recent months. Canadian adult-use cannabis remains highly competitive, and Cronos has no plant-touching U.S. operations, so federal rescheduling headlines affect sentiment more than direct financials. Bernstein's below-market $2.47 target reflects skepticism that current momentum can be sustained, and cannabis equities as a group remain volatile and sentiment-driven.
The $3.61 level marks the 52-week high and the clearest resistance zone; a move toward $3.75 would require a breakout above it. On the downside, the roughly $3.00–$3.07 area, which includes the post-earnings gap from August, is a nearby support level, with deeper support near $2.72–$2.80. The stock's climb from around $2.28 to above $3.35 over the past year reflects a firming uptrend, but its position near the top of the range leaves little room for disappointment if earnings or sector sentiment soften.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary and some targets referenced here were issued at different points in 2026. The next major catalyst is the Q3 2026 earnings report scheduled for early November, where investors will focus on revenue growth, international performance, gross margin, and any commentary on cash deployment and U.S. regulatory positioning. Analysts' revisions around that report and any further target changes will be key signals of whether the higher end of the target range remains intact.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like CRON, this type of tool can help traders spot shifting trends, discover new opportunities, and monitor existing positions more efficiently than manual chart review alone. Traders interested in a more systematic, data-driven approach to timing entries and exits can explore these AI-generated signals as part of their broader research process.
Reaching $3.75 would require a modest but notable move of about 12% and a breakout above the 52-week high. The bull case rests on a record quarter, strong top-line growth, international expansion, and a fortress-like cash position, while the bear case centers on expected near-term earnings moderation, intense Canadian competition, regulatory uncertainty, and wide disagreement among analysts. Because the overall average analyst target sits below the current price, the $3.75 figure reflects only the more optimistic end of the range and should not be read as a consensus. Whether the stock sustains its advance will depend heavily on the November earnings report and whether the company can convert its recent momentum into durable, repeatable profitability.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
|---|---|---|---|---|
| CRON | 100% | -0.89% | ||
| SNDL - CRON | 73% Closely correlated | -0.77% | ||
| ACB - CRON | 59% Loosely correlated | -1.69% | ||
| TLRY - CRON | 58% Loosely correlated | -2.89% | ||
| CGC - CRON | 58% Loosely correlated | -1.81% | ||
| TRLV - CRON | 55% Loosely correlated | -0.47% | ||
More | ||||
| Ticker / NAME | Correlation To CRON | 1D Price Change % |
|---|---|---|
| CRON | 100% | -0.89% |
| CRON (2 stocks) | 82% Closely correlated | +0.05% |
| Pharmaceuticals: Generic (83 stocks) | 3% Poorly correlated | +0.86% |